Lantern Pharma (LTRN) Q3 2024 earnings summary

Executive summary

• Advanced three AI-guided oncology drug candidates (LP-300, LP-184, LP-284) in active Phase 1 and 2 trials, with additional ADC-based preclinical molecules under evaluation and expansion of the Harmonic trial (LP-300) into Asia targeting never-smoker NSCLC.

• LP-184 received FDA Fast Track Designation for glioblastoma and three Rare Pediatric Disease Designations, increasing potential for Priority Review Vouchers.

• Over 50 patients dosed in LP-184 and LP-284 Phase 1 trials with no dose-limiting toxicities observed; LP-300 Harmonic trial showed 86% clinical benefit rate in initial cohort.

• Established Starlight Therapeutics as a CNS and brain cancer-focused subsidiary, with plans for Phase 1b/2 trials in 2025 and a distinguished scientific advisory board.

• Published multiple scientific papers and presented at major oncology conferences, highlighting AI-powered approaches and combination regimens.

Financial highlights

• Q3 2024 net loss was $4.5 million ($0.42 per share), compared to $3.2 million ($0.29 per share) in Q3 2023, driven by increased R&D and G&A expenses.

• R&D expenses rose to $3.7 million for Q3 2024, up 68% year-over-year, reflecting higher clinical trial activity.

• Cash, cash equivalents, and marketable securities totaled $28.1 million as of September 30, 2024, providing runway into at least late 2025.

• Interest and other income increased to $674,000 in Q3 2024.

• Weighted average shares outstanding: 10.76 million for Q3 2024.

Outlook and guidance

• Expect to complete LP-184 Phase 1a enrollment by year-end 2024 or January 2025, with initial safety and molecular data in late 2024 or early 2025.

• Plan to launch Phase 1b/2 trials for Starlight Therapeutics in early 2025, pending financing and site selection.

• Anticipate interim analysis and expanded data from the Harmonic trial (LP-300) in Asia by mid-2025.

• Continue to pursue additional collaborations, licensing, and partnerships, especially in Asia and with larger biopharma companies.